NewsMeter
Nine seats now constitute the Immunic, Inc. (IMUX) board of directors, reduced from ten, after Dr. Duane Nash resigned his directorship effective September 10, 2026.
Chief Executive Officer Erik Lundgren signed the SEC 8-K disclosing the governance change on September 11.
The filing's Item 5.02 states Nash's exit was not the result of any disagreement with the company on any matter relating to its operations, policies, or practices.
The board voted by resolution to absorb the vacancy rather than replace it. No incoming director or search process was announced alongside the disclosure.
Keep reading